Polycythemia risk factors: Difference between revisions

Jump to navigation Jump to search
Line 19: Line 19:


==Risk Factors==
==Risk Factors==
There are no established risk factors for [disease name].


OR
*One of the most common and most dangerous complications of polycythemia vera is thrombus formation. The risk factors are as follows:
 
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
 
OR
 
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
===Common Risk Factors===
*Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
*Common risk factors in the development of [disease name] include:
**[Risk factor 1]
**[Risk factor 2]
**[Risk factor 3]
 
===Less Common Risk Factors===
*Less common risk factors in the development of [disease name] include:
**[Risk factor 1]
**[Risk factor 2]
**[Risk factor 3]


*Women- usually younger at the time of diagnosis, have a higher risk of arterio-venous thrombosis.
*Mutation- higher burden of JAK2V617F allele
*Inflammatory markers- Pentraxins play an important role: increased hs-CRP and a lower PTX3 have a higher risk of thrombosis
*Presence of microparticles- responsible for decreased thrombin inhibition, increased CD41, and an increased chance of splenomegaly
*Neutrophil Extracellular Trap formations- NETosis and apoptosis <ref name="url[Full text] Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Man | JBM">{{cite web |url=https://www.dovepress.com/polycythemia-vera-associated-complications-pathogenesis-clinical-manif-peer-reviewed-fulltext-article-JBM |title=[Full text] Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Man &#124; JBM |format= |work= |accessdate=}}</ref>


==References==
==References==

Revision as of 01:00, 10 December 2020

Polycythemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycythemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polycythemia risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycythemia risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycythemia risk factors

CDC on Polycythemia risk factors

Polycythemia risk factors in the news

Blogs on Polycythemia risk factors

Directions to Hospitals Treating Polycythemia

Risk calculators and risk factors for Polycythemia risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]

Overview

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Risk Factors

  • One of the most common and most dangerous complications of polycythemia vera is thrombus formation. The risk factors are as follows:
  • Women- usually younger at the time of diagnosis, have a higher risk of arterio-venous thrombosis.
  • Mutation- higher burden of JAK2V617F allele
  • Inflammatory markers- Pentraxins play an important role: increased hs-CRP and a lower PTX3 have a higher risk of thrombosis
  • Presence of microparticles- responsible for decreased thrombin inhibition, increased CD41, and an increased chance of splenomegaly
  • Neutrophil Extracellular Trap formations- NETosis and apoptosis [1]

References

  1. "[Full text] Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Man | JBM".

Template:WS Template:WH